SCHEMBL16260

SCHEMBL16260

CC(O)(c1ccc(N2CCN(S(=O)(=O)c3cccs3)C[C@H]2CN2CCOC[C@H]2CO)cc1)C(F)(F)F

nearest known ligand 0.84

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCK P35557 12/20 0.84
GCKR Q14397 8/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18639 1.00 GCK (0.84) GCKGCKR
SCHEMBL18339 1.00 GCK (0.84) GCKGCKR
SCHEMBL12078570 1.00 GCK (0.84) GCKGCKR
SCHEMBL12079346 1.00 GCK (0.84) GCKGCKR
SCHEMBL16846 1.00 GCK (0.84) GCKGCKR
SCHEMBL18263 1.00 GCK (0.84) GCKGCKR
SCHEMBL33131 1.00 GCK (0.84) GCKGCKR
SCHEMBL20768 1.00 GCK (0.84) GCKGCKR
SCHEMBL16065 1.00 GCK (0.84) GCKGCKR
SCHEMBL17868 1.00 GCK (0.84) GCKGCKR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed